175 filings
Page 2 of 9
8-K
a72dtqyexgy
12 Jun 23
Termination of a Material Definitive Agreement
7:19am
8-K
nfmj0ql
9 Jun 23
Departure of Directors or Certain Officers
4:11pm
8-K
vwn9v
22 May 23
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
7:04am
8-K
u10jy uh6sy0hz8rx4
18 May 23
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of
7:11am
8-K
u2hnpxkf
11 May 23
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
7:20am
ARS
p70v3 88i0
5 May 23
Annual report to shareholders
4:00pm
8-K
o6nboaeql 3k
1 May 23
AVROBIO Announces Leadership Transition
7:40am
S-8
96ee 2iuks1z
23 Mar 23
Registration of securities for employees
4:58pm
8-K
w569 ct8blhc7flvo0
23 Mar 23
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
7:11am
8-K
90mudxxlcqz8xmonemko
27 Feb 23
Other Events
4:39pm
8-K
bjy r3lv1u3
7 Dec 22
Regulation FD Disclosure
7:37am
8-K
n1nptrb7mbq5xw kwcv
8 Nov 22
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
7:15am
8-K
vwkomu40jdkoh9z2
7 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm
8-K
97m948uyyqy1nl
9 Aug 22
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
7:11am